Dr Natasha Martin
DPhil (Oxon)
Current positions
Visiting Professor
Bristol Medical School (PHS)
Contact
Press and media
Many of our academics speak to the media as experts in their field of research. If you are a journalist, please contact the University’s Media and PR Team:
Research interests
I am an infectious disease modeller based in the Department of Social and Community Medicine, University of Bristol and the Social and Mathematical Epidemiology Group, Department of Global Health and Development, LSHTM. I am currently working with Professor Matthew Hickman and Dr. Peter Vickerman on mathematical models of hepatitis C and HIV prevention among people who inject drugs. Specifically, the majority of my work centres on modeling the impact, cost-effectiveness, and optimal program delivery of HCV treatment as prevention. Additionally, I have worked on economic evaluations and modelling analyses for the National Institute for Clinical Excellence (NICE) and the World Health Organization.
I completed my DPhil in 2009 at the Centre for Mathematical Biology at Oxford University under the supervision of Professor Philip Maini and Dr. Eamonn Gaffney. My thesis focused on mathematical models of tumour acidity and invasion.
Previously, during my undergraduate at Stanford University, I researched phenotypic plasticity of barnacle leg lengths with Professor Mark Denny and mathematical models of chronic myelogenous leukemia with Dr. Helen Moore.
Publications
Recent publications
25/02/2025Quantifying the impact of a large‐scale opioid agonist treatment program on suicide prevention in New South Wales, Australia
Addiction
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies
The Lancet HIV
Cost-Effectiveness of a Police Education Program on HIV and Overdose among People Who Inject Drugs in Tijuana, Mexico
The Lancet Regional Health - Americas
Under threat
Lancet (London, England)
Determining herd immunity thresholds for hepatitis A virus transmission to inform vaccination strategies among people who inject drugs in 16 U.S. States
Clinical Infectious Diseases